Dedifferentiated Liposarcoma: Systemic Therapy Options

Opinion statementOver the last several years, the systemic treatment landscape for dedifferentiated liposarcoma (DDLPS) has notably expanded. Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel, that were shown to have efficacy in unselected populations of patients with soft tissue sarcomas. More recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib in patients with advanced liposarcoma and DDLPS. Additionally, there are several investigational targeted therapies that have incorporated advances in the understanding of DDLPS disease biology, exploiting the fact that nearly all such tumors include highly amplified expression of MDM2 and CDK4. Recent clinical trials have supported the benefit of the CDK4 inhibitor abemaciclib and the nuclear export inhibitor selinexor and support continued development of anti-MDM2 therapies, with particular attention to the bone marrow toxicity and resultant thrombocytopenia that has thus far limited their use. In contrast, the checkpoint inhibitors pembrolizumab and nivolumab remain of questionable benefit, although these immunotherapy drugs may have a role when combined with other therapeutic agents. Ongoing phase III trials will clarify the role of these novel agents. Future directions include directly comparin...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Abstract The aim of the present study was to investigate the impact of the combined use of corticosteroid on adverse events (AEs) induced by enzalutamide (Enz) in patients with metastatic castration-resistant prostate cancer (mCRPC). The cohort of the present study included 121 consecutive patients with mCRPC who sequentially received androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and Enz, in any order, without prior docetaxel therapy. Detailed assessments of AEs during treatment with Enz were conducted according to whether or not corticosteroid was administered. Of these patients, 63 and ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Authors: Chen SM, Lin KT, Dai YH, Chiang KT, Lee SY Abstract For nasopharyngeal carcinoma (NPC), radiotherapy is the primary treatment. However, complications occur after radiation to the nasopharynx, which could potentially affect the flying safety. Four fighter pilots with NPC were reported. With early to locally advanced NPC, they received radiotherapy with or without concurrent chemotherapy. The prescribed radiation dose was 70 Gy to the primary tumor over the nasopharynx. Before treatment, all patients presented with various degrees of hearing loss on pure tone audiometry (main frequencies of 20-45 dB at 3-4.5...
Source: Military Medicine - Category: International Medicine & Public Health Tags: Mil Med Source Type: research
Condition:   Colorectal Cancer Interventions:   Drug: mFOLFOXIRI adjuvant chemotherapy;   Drug: mFOLFOX6 adjuvant chemotherapy Sponsor:   Sun Yat-sen University Recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Advanced Colorectal Cancer Interventions:   Drug: AL2846;   Drug: Calcium folate;   Drug: 5-FU;   Drug: Oxaliplatin;   Drug: Irinotecan Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Ovarian Cancer Interventions:   Drug: Doxorubicin Hydrochloride Liposome Injection+carboplatin;   Drug: paclitaxel +carboplatin Sponsor:   Hunan Cancer Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Conclusions: miRNAs affect virtually all mechanisms of carcinogenesis, working as either oncogenes or tumor suppressor genes. In this systematic review we identified miRNAs that may be related to prognosis, diagnosis, and chemotherapy sensitivity. The 12 miRNAs identified here should be included in future studies for validation. PMID: 32256980 [PubMed - as supplied by publisher]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Assoun EN, Meyer AN, Jiang MY, Baird SM, Haas M, Donoghue DJ Abstract Prostate cancer affects hundreds of thousands of men and families throughout the world. Although chemotherapy, radiation, surgery, and androgen deprivation therapy are applied, these therapies do not cure metastatic prostate cancer. Patients treated by androgen deprivation often develop castration resistant prostate cancer which is incurable. Novel approaches of treatment are clearly necessary. We have previously shown that prostate cancer originates as a stem cell disease. A prostate cancer patient sample, #87, obtained from prostatecto...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Hazim A, Mills G, Prasad V, Haslam A, Chen EY Abstract BACKGROUND: As progress continues in oncology drug development, this study aimed to examine whether the previously established association between drug dose and efficacy in the era of cytotoxic therapies remains true in today's phase I dose-escalation oncology trials. METHODS: A systematic review of early-phase dose-finding trials of single-agent oncology drugs from 2015 to 2018 was conducted to examine the relationship between drug dose and objective responses. Cancer-specific trials were included if they determined maximum tolerated dose (MTD) an...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
CONCLUSIONS: Within the limitations of this retrospective analysis, patients with advanced ovarian cancer treated by high-frequency-imaging providers had earlier detection of recurrence. Future analyses in a larger population are warranted to elucidate the risks versus benefits of surveillance imaging. PMID: 32259789 [PubMed - as supplied by publisher]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusion Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Phase I and Clinical Pharmacology, Osteosarcoma & Ewing Sarcomas:, Rhabdo & Other Soft Tissue Sarcomas: Source Type: research
More News: Biology | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Immunotherapy | Liposarcoma | Sarcomas | Soft Tissue Sarcoma | Taxotere | Thrombocytopenia | Toxicology